派格生物医药－Ｂ 02565Stock Information

Stock Information · Old Rules
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
// Company Overview //
Stock Name派格生物医药－Ｂ
Stock Code02565
Company Full Name派格生物医药－Ｂ
Industry醫療保健
Principal Activities公司成立于2008年，是一家專注于自主研究及開發慢性病創新療法的生物技術公司，重點關注內分泌代謝領域。
Listing Date2025-05-27
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市拱墅區皓章大廈1幢606室
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttps://www.pegbio.com/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo
// Offering Information //
Offering Mechanism 机制A(旧)
Clawback Tiers因超购743.8倍，回拨至50.0%
Offer Period2025-05-19 to 2025-05-22
Offer PriceHK$ 15.60 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,800
Par ValueNo data
Global Offering Shares19,283,500
HK Public Offering Shares9,642,000 (50.0%)
International Placing Shares9,641,500 (50.0%)
Offer RatioNo data
Total Shares Post-IPONo data
Total Global Offering SizeHK$ 300,822,600
Public Offering SizeHK$ 150,415,200 (50.0%)
Oversubscription Multiple743.8x
Valid Applications49,627
Accepted Applications10,396
ReallocationNo
Total Funds RaisedHK$ 150,415,200
Greenshoe (Over-allotment Option)No
Final Public Offering Share50.0%
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
Pre-IPO Valuation (Last Round)No data
P/E Ratio-19.93
Profit/Loss StatusNo data
Period-End Cash BalanceNo data
Listing Expenses~HK$ 69,100,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 13.0
First Day Change-25.90%
First Day Volume11264800.0
First Day Turnover150891000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約116.5百萬港元（或約50.2%）用于撥付核心產品PB-119的商業化及適應癥擴展； 2、約79.9百萬港元（或約34.5%）用于撥付主要產品PB-718的進一步開發； 3、約12.2百萬港元（或約5.3%）用于撥付其他管線候選產品正在進行及計劃進行的研發； 4、約2.3百萬港元（或約1.0%）將用于業務開發活動及加強海外業務； 5、約20.9百萬港元（或約9.0%）將用作營運資金及其他一般公司用途。
// Underwriting Syndicate //
独家保荐人 (1)
中国国际金融香港证券有限公司
整体协调人 (5)
中国国际金融香港证券有限公司 民银证券有限公司 农银国际证券有限公司 中银国际亚洲有限公司 建银国际金融有限公司
联席账簿管理人 (14)
中国国际金融香港证券有限公司 民银证券有限公司 农银国际证券有限公司 中银国际亚洲有限公司 建银国际金融有限公司 利弗莫尔证券有限公司 中泰国际证券有限公司 浦银国际融资有限公司 艾德证券期货有限公司 国金证券（香港）有限公司 中国光大证券（香港）有限公司 广发证券(香港)经纪有限公司 中国银河国际证券（香港）有限公司 光银国际资本有限公司
联席牵头经办人 (14)
中国国际金融香港证券有限公司 民银证券有限公司 农银国际证券有限公司 中银国际亚洲有限公司 建银国际金融有限公司 利弗莫尔证券有限公司 中泰国际证券有限公司 浦银国际融资有限公司 艾德证券期货有限公司 国金证券（香港）有限公司 中国光大证券（香港）有限公司 广发证券(香港)经纪有限公司 中国银河国际证券（香港）有限公司 光银国际资本有限公司
// Cornerstone Investors // Allotment Results Announcement
#Investor NameShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 MinglyChinaGrowthFund, 34,852,074 6.24% 9.03% 2026-05-26 2026-05-26
2 上海蘇頡企業管理諮詢合夥企業（有 29,175,230 10.45% 7.56% 2026-05-26 2026-05-26
3 TrueWingLimited 15,482,756 5.55% 4.01% 2026-05-26 2026-05-26
4 妙譽有限公司 14,541,239 5.21% 3.77% 2026-05-26 2026-05-26
5 凱風創業投資有限公司 12,805,764 4.59% 3.32% 2026-05-26 2026-05-26
6 天士力（香港）藥業有限公司 12,740,586 4.56% 3.30% 2026-05-26 2026-05-26
7 上海曜萃投資中心（有限合夥） 12,213,941 2.63% 3.16% 2026-05-26 2026-05-26
8 蘇州工業園區中鑫惠遠投資中心 11,705,026 0.36% 3.03% 2026-05-26 2026-05-26
9 蘇州工業園區新建元生物創業投資企 11,339,959 4.06% 2.94% 2026-05-26 2026-05-26
10 ShareLinkCapitalCo.,Ltd. 9,752,279 3.49% 2.53% 2026-05-26 2026-05-26
11 杭州泰格股權投資合夥企業 9,634,137 3.45% 2.50% 2026-05-26 2026-05-26
12 限公司（「益澤康瑞」） 9,584,500 49.70% 3.43% — —
13 平潭盈科盛鑫創業投資合夥企業 8,468,396 2.19% — 2026-05-26 2026-05-26
14 前海股權投資基金（有限合夥） 8,290,415 2.97% 2.15% 2026-05-26 2026-05-26
15 ChelmsfordInternationalLimited 7,151,567 2.56% 1.85% 2026-05-26 2026-05-26
16 白林女士 6,810,871 2.44% 1.76% 2026-05-26 2026-05-26
17 湖州啟緣致欣股權投資合夥企業 5,452,433 1.41% — 2026-05-26 2026-05-26
18 蘇州工業園區產業投資基金（有限合 5,089,142 1.32% — 2026-05-26 2026-05-26
19 蘇州翼樸二號股權投資合夥企業 4,839,104 1.73% 1.25% 2026-05-26 2026-05-26
20 平潭浦信盈科睿遠創業投資合夥企業 4,455,203 1.60% 1.15% 2026-05-26 2026-05-26
21 香港泰格醫藥科技有限公司（「香港泰 4,247,204 1.52% 1.10% 2026-05-26 2026-05-26
22 北京敏捷之道諮詢有限公司 4,246,946 0.13% 1.10% 2026-05-26 2026-05-26
23 淄博盈科吉運創業投資合夥企業 4,071,314 1.05% — 2026-05-26 2026-05-26
24 AsiaPrivateEquityCapital 3,780,075 1.35% 0.98% 2026-05-26 2026-05-26
25 中原前海股權投資基金（有限合夥） 3,562,399 1.28% 0.92% 2026-05-26 2026-05-26
26 蘇州工業園區新建元二期創業投資企 3,201,273 1.15% 0.83% 2026-05-26 2026-05-26
27 石河子市鑫悅股權投資合夥企業 3,201,273 1.15% 0.83% 2026-05-26 2026-05-26
28 YuanBioVentureCapital 3,113,437 1.12% 0.81% 2026-05-26 2026-05-26
29 蘇州工業園區新建元三期創業投資企 2,646,354 0.95% 0.69% 2026-05-26 2026-05-26
30 杭州泰譽四期創業投資合夥企業 1,817,998 0.65% 0.47% 2026-05-26 2026-05-26
// Directors & Management //
ChairmanMichael Min XU
Company Secretary黃一峰,郭恩廷
No director data available.
// Major Shareholders //
Major Shareholders & HoldingsMichael Min XU(15.05%),Mingly China Growth Fund, L.P.(9.03%),上海蘇頡企業管理咨詢合伙企業(有限合伙)(7.56%),元生創投(5.26%)
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
500 18,543 1,483 0.08
1,000 4,139 414 0.10
1,500 2,155 217 0.10
2,000 1,699 180 0.11
2,500 1,235 133 0.11
3,000 1,421 162 0.11
3,500 498 58 0.12
4,000 485 58 0.12
4,500 351 43 0.12
5,000 2,638 330 0.12
6,000 1,095 138 0.13
7,000 871 110 0.13
8,000 535 68 0.13
9,000 344 45 0.13
10,000 2,478 330 0.13
15,000 1,507 279 0.19
20,000 1,167 283 0.24
25,000 824 246 0.30
30,000 716 253 0.35
35,000 451 182 0.41
40,000 383 174 0.46
45,000 267 134 0.50
50,000 882 481 0.55
60,000 504 324 0.65
70,000 368 271 0.74
80,000 301 249 0.83
90,000 215 196 0.92
100,000 895 895 1.00
150,000 503 33 1.08
200,000 299 120 1.40
250,000 194 131 1.70
300,000 313 313 1.98
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
350,000 674 674 6.02
400,000 105 67 6.64
450,000 41 33 6.84
500,000 79 79 7.00
550,000 47 7 7.15
600,000 33 17 7.56
650,000 32 32 8.06
700,000 58 23 8.40
750,000 32 22 8.70
800,000 20 20 8.96
850,000 24 8 9.35
964,000 206 206 10.03
Offer Ratio
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics